X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2588) 2588
female (2242) 2242
middle aged (1947) 1947
oncology (1637) 1637
adult (1632) 1632
aged (1596) 1596
epirubicin - administration & dosage (1549) 1549
antineoplastic combined chemotherapy protocols - therapeutic use (1395) 1395
epirubicin (1376) 1376
antineoplastic combined chemotherapy protocols - adverse effects (1227) 1227
chemotherapy (1130) 1130
male (1106) 1106
breast neoplasms - drug therapy (1105) 1105
epirubicin - adverse effects (1000) 1000
index medicus (934) 934
treatment outcome (766) 766
cancer (730) 730
doxorubicin (643) 643
breast cancer (638) 638
fluorouracil - administration & dosage (633) 633
cyclophosphamide - administration & dosage (607) 607
breast neoplasms - pathology (514) 514
drug administration schedule (472) 472
antineoplastic combined chemotherapy protocols - administration & dosage (469) 469
therapy (456) 456
cyclophosphamide (455) 455
cisplatin - administration & dosage (447) 447
anthracyclines (417) 417
disease-free survival (410) 410
epirubicin - therapeutic use (398) 398
neoplasm staging (396) 396
chemotherapy, adjuvant (369) 369
cisplatin (361) 361
cyclophosphamide - adverse effects (347) 347
paclitaxel (340) 340
docetaxel (332) 332
survival rate (327) 327
doxorubicin - adverse effects (323) 323
fluorouracil - adverse effects (312) 312
fluorouracil (311) 311
doxorubicin - administration & dosage (310) 310
carcinoma (307) 307
survival analysis (291) 291
paclitaxel - administration & dosage (290) 290
antibiotics, antineoplastic - adverse effects (287) 287
medicine & public health (283) 283
trial (282) 282
dose-response relationship, drug (280) 280
pharmacology & pharmacy (273) 273
antibiotics, antineoplastic - administration & dosage (268) 268
prospective studies (267) 267
follow-up studies (265) 265
care and treatment (263) 263
survival (262) 262
combined modality therapy (252) 252
prognosis (248) 248
aged, 80 and over (246) 246
adjuvant chemotherapy (235) 235
taxoids - administration & dosage (234) 234
neoplasm metastasis (215) 215
retrospective studies (214) 214
antineoplastic agents - adverse effects (210) 210
adenocarcinoma - drug therapy (209) 209
breast neoplasms - surgery (209) 209
stomach neoplasms - drug therapy (208) 208
deoxycytidine - analogs & derivatives (205) 205
research (205) 205
5-fluorouracil (203) 203
breast neoplasms - mortality (203) 203
adolescent (192) 192
analysis (183) 183
toxicity (183) 183
surgery (182) 182
combination (181) 181
deoxycytidine - administration & dosage (175) 175
cisplatin - adverse effects (174) 174
drug therapy (174) 174
neoadjuvant therapy (171) 171
risk factors (171) 171
infusions, intravenous (169) 169
time factors (168) 168
cardiotoxicity (165) 165
neutropenia - chemically induced (164) 164
capecitabine (163) 163
antibiotics, antineoplastic - therapeutic use (161) 161
adjuvant treatment (159) 159
antineoplastic agents - therapeutic use (158) 158
clinical trials (158) 158
health aspects (154) 154
doxorubicin - therapeutic use (152) 152
phase-ii (150) 150
methotrexate (149) 149
paclitaxel - adverse effects (149) 149
trastuzumab (147) 147
metastasis (146) 146
randomized-trial (146) 146
lung neoplasms - drug therapy (144) 144
antineoplastic agents - administration & dosage (142) 142
tumors (142) 142
neoadjuvant chemotherapy (141) 141
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2629) 2629
Japanese (80) 80
Chinese (40) 40
German (29) 29
French (24) 24
Spanish (14) 14
Italian (12) 12
Polish (7) 7
Bulgarian (4) 4
Hungarian (3) 3
Russian (3) 3
Danish (2) 2
Portuguese (2) 2
Czech (1) 1
Korean (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, ISSN 0080-0015, 1980, Volume 74, pp. 192 - 199
4'-Epidoxorubicin (epi-DXR) was tested in 56 patients with various types of advanced malignancies. The pattern of acute toxicity was similar to that of... 
Doxorubicin - therapeutic use | Humans | Middle Aged | Drug Evaluation | Antibiotics, Antineoplastic - adverse effects | Male | Blood Cell Count | Neoplasms - drug therapy | Antibiotics, Antineoplastic - therapeutic use | Adolescent | Electrocardiography | Adult | Female | Aged | Epirubicin | Doxorubicin - adverse effects
Journal Article
Cancer Treatment Reports, ISSN 0361-5960, 1982, Volume 66, Issue 9, pp. 1757 - 1758
Journal Article
Tumori, ISSN 0300-8916, 1982, Volume 68, Issue 5, pp. 431 - 433
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 10/1983, Volume 106, Issue 2, pp. 148 - 152
4'-Epi-doxorubicin, one of the analogs of doxorubicin, was shown in experimental animal tumor models to have a wide spectrum of antitumor activity. In... 
4′-Epi-doxorubicin | Phase-II trial | Solid tumors | ONCOLOGY | Doxorubicin - therapeutic use | Humans | Middle Aged | Drug Evaluation | Male | Neoplasms - drug therapy | Neoplasm Metastasis | Antibiotics, Antineoplastic - therapeutic use | Heart - drug effects | Adult | Female | Aged | Epirubicin | Doxorubicin - adverse effects
Journal Article
Investigational New Drugs, ISSN 0167-6997, 12/1983, Volume 1, Issue 4, pp. 349 - 353
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 1983, Volume 10, Issue 1, pp. 1 - 22
Journal Article
Cancer treatment reports, ISSN 0361-5960, 04/1983, Volume 67, Issue 4, pp. 337 - 341
4'-Epi-doxorubicin (4'e-Dx) was used as a single agent in a broad phase II study involving a variety of advanced metastatic tumors. A total of 115 patients... 
Doxorubicin - therapeutic use | Humans | Middle Aged | Drug Evaluation | Antibiotics, Antineoplastic - adverse effects | Male | Neoplasms - drug therapy | Neoplasm Metastasis | Antibiotics, Antineoplastic - therapeutic use | Adolescent | Adult | Female | Aged | Epirubicin | Doxorubicin - adverse effects
Journal Article
American journal of clinical oncology, ISSN 0277-3732, 10/1983, Volume 6, Issue 5, pp. 553 - 554
Journal Article
International Journal of Clinical Pharmacology Research, ISSN 0251-1649, 1984, Volume 4, Issue 3, pp. 231 - 238
Eight cancer patients were given 4'-epi-DX and DX (70 mg/m2) by i.v. route at three-week intervals according to a randomized cross-over design. Blood samples... 
Doxorubicin - blood | Doxorubicin - therapeutic use | Hematologic Diseases - chemically induced | Injections, Intravenous | Humans | Middle Aged | Male | Neoplasms - drug therapy | Neoplasms - blood | Models, Biological | Female | Aged | Epirubicin | Kinetics | Doxorubicin - adverse effects
Journal Article
Tumori, ISSN 0300-8916, 1984, Volume 70, Issue 3, pp. 297 - 300
Thirty-four evaluable patients with metastatic colorectal carcinoma (13 rectal primary and 21 colonic primary, 4 pretreated and 30 untreated) received... 
Doxorubicin - therapeutic use | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Drug Evaluation | Antibiotics, Antineoplastic - adverse effects | Male | Neoplasm Metastasis | Antibiotics, Antineoplastic - therapeutic use | Adult | Female | Aged | Epirubicin | Rectal Neoplasms - drug therapy | Doxorubicin - adverse effects
Journal Article
European Journal of Cancer and Clinical Oncology, ISSN 0277-5379, 1984, Volume 20, Issue 4, pp. 495 - 499
Epirubicin, a steroisomer of doxorubicin with suggested lower potential for cardiotoxicity in animal tumor systems, was evaluated in a disease-oriented phase... 
Doxorubicin - therapeutic use | Lung Neoplasms - drug therapy | Carcinoma, Squamous Cell - drug therapy | Antibiotics, Antineoplastic - therapeutic use | Time Factors | Carcinoma, Small Cell - drug therapy | Humans | Drug Evaluation | Aged | Epirubicin | Adenocarcinoma - drug therapy | Doxorubicin - adverse effects
Journal Article
Cancer Treatment Reports, ISSN 0361-5960, 1984, Volume 68, Issue 4, pp. 675 - 677
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 02/1984, Volume 107, Issue 1, pp. 38 - 41
Journal Article
Oncology, ISSN 0030-2414, 1984, Volume 41, Issue 6, pp. 383 - 386
Epidoxorubicin (EDX) was administered to a group of 26 patients with acute leukaemia or lymphoma, replacing either daunorubicin or doxorubicin (DXR) as a... 
Doxorubicin - therapeutic use | Acute Disease | Humans | Middle Aged | Leukemia - drug therapy | Male | Clinical Trials as Topic | Lymphoma - drug therapy | Antibiotics, Antineoplastic - therapeutic use | Adult | Female | Aged | Epirubicin | Doxorubicin - adverse effects
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.